Join myLiquitab at the 17th Alzheimer’s Australia Biennial National Dementia Conference #BeTheChage2017 17 to 20 October 2017 at The Melbourne Convention and Exhibition Centre. The conference entitled BE THE CHANGE focuses on innovative and creative ways of enhancing the quality of life of dementia patients and their families and carers. Visit myLiquitab at BOOTH 28 [...]
The Leading Aged Services Australia (LASA) National Conference last 15 to 18 October at the Gold Coast Convention and Exhibition Centre was a huge success. We appreciate everyone who visited our booth and experienced our demonstration of the myLiquitab technology.
The World Health Organization (WHO) launched the Better Medicines for Children (BMC) initiative which promotes the development of child-friendly medications in 2007. The BMC addresses the need to improve medication formulations and focus on making medicines that are suitable for children. In a 2015 report by the Pan American Health Organization, approximately 1000 children die [...]
Join myLiquitab at the PSA17 in Sydney, on July 28 to 30, 2017. The event will be held at The Hyatt Regency Sydney, in Darling Harbour (formerly Four Points by Sheraton). PSA17 is the Pharmaceutical Society of Australia’s flagship annual conference attended by pharmacists, industry leaders and health professionals who want to help shape the [...]
According to Chandra M. Ivey, MD, director of laryngology, voice, and swallowing disorders at Columbia Doctors Eastside in New York City, “dysphagia affects between 7% and 35% of the population.” This statistics is higher among adults. Adult dysphagia can be mild and easily overlooked. Ivey noted that half of dysphagia patients do not discuss their [...]
The Medicines Manufacturing Innovation Centre (MMIC), Monash University commenced a far reaching investigation into the myliquitab technology in March 2017. MMIC has completed the first phase of their independent evaluation and characterization of the myLiquitab Homecare dispersion unit. The interim report provides evaluation of the myLiquitab system covering a range of representative tablets from granulated [...]
myLiquitab is pleased to advise it has closed an equity funding round. The proceeds will be used to manufacture production tooling, procure the materials and components and pay for labour for the first batch of ‘beta’ production myLiquitab units, and for working capital. mLiquitab is targeting a beta release of units in mid-2016 for user [...]